Exelixis Operating Cash Flow Sales Ratio from 2010 to 2025

EXEL Stock  USD 36.85  1.76  5.02%   
Exelixis Operating Cash Flow Sales Ratio yearly trend continues to be quite stable with very little volatility. The value of Operating Cash Flow Sales Ratio is projected to decrease to 0.28. From the period between 2010 and 2025, Exelixis, Operating Cash Flow Sales Ratio regression line of its data series had standard deviation of  2.99 and standard deviation of  2.99. View All Fundamentals
 
Operating Cash Flow Sales Ratio  
First Reported
2010-12-31
Previous Quarter
0.32276049
Current Value
0.27931176
Quarterly Volatility
2.99273674
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Exelixis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Exelixis' main balance sheet or income statement drivers, such as Interest Expense of 64.9 M, Total Revenue of 2.3 B or Gross Profit of 2.3 B, as well as many indicators such as Price To Sales Ratio of 4.01, Dividend Yield of 0.0 or PTB Ratio of 2.6. Exelixis financial statements analysis is a perfect complement when working with Exelixis Valuation or Volatility modules.
  
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.

Latest Exelixis' Operating Cash Flow Sales Ratio Growth Pattern

Below is the plot of the Operating Cash Flow Sales Ratio of Exelixis over the last few years. It is Exelixis' Operating Cash Flow Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Exelixis' overall financial position and show how it may be relating to other accounts over time.
Operating Cash Flow Sales Ratio10 Years Trend
Slightly volatile
   Operating Cash Flow Sales Ratio   
-0.0961-3.81-6.34-9.370.210.280.32100%
       Timeline  

Exelixis Operating Cash Flow Sales Ratio Regression Statistics

Arithmetic Mean(1.54)
Geometric Mean0.61
Coefficient Of Variation(194.21)
Mean Deviation2.43
Median0.21
Standard Deviation2.99
Sample Variance8.96
Range9.6973
R-Value0.59
Mean Square Error6.25
R-Squared0.35
Significance0.02
Slope0.37
Total Sum of Squares134.35

Exelixis Operating Cash Flow Sales Ratio History

2022 0.32
2021 0.28
2016 0.21
2014 -9.37
2013 -6.34
2011 -3.81
2010 -0.0961

About Exelixis Financial Statements

Exelixis investors utilize fundamental indicators, such as Operating Cash Flow Sales Ratio, to predict how Exelixis Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cash Flow Sales Ratio 0.32  0.28 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out the analysis of Exelixis Correlation against competitors.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.754
Earnings Share
1.76
Revenue Per Share
7.478
Quarterly Revenue Growth
0.182
Return On Assets
0.1464
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…